Peri-Implantitis Treatment Market revenue to surpass USD 5 Billion by 2035, says Research Nester
September 28, 2023 05:00 ET
|
Research Nester
New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The global peri-implantitis treatment market size is projected to expand at ~8% CAGR between 2023 and 2035. The market is expected to garner a revenue of...
Nonvenereal Syphilis Treatment Market revenue to hit USD 440 Million by 2035, says Research Nester
September 26, 2023 07:30 ET
|
Research Nester
New York, Sept. 26, 2023 (GLOBE NEWSWIRE) -- The global nonvenereal syphilis treatment market size is predicted to grow at a CAGR of over ~9% from 2023 to 2035. The market is projected to garner a...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
Andira Pharmaceuticals’ US Patent Allowed in Breakthrough Therapeutic Treatment to Address Deadly Antibiotic-Resistant Infections
August 10, 2023 08:00 ET
|
US Capital Global
San Francisco, California, USA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million...
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023 07:30 ET
|
OpGen, Inc.
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023 07:30 ET
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
June 07, 2023 01:15 ET
|
Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero...
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
May 08, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...
Summit Announces Results of Court Meeting and General Meeting
August 19, 2020 16:01 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Results of Court Meeting and General Meeting Oxford, UK, and Cambridge, MA, US, August 19, 2020 – Summit Therapeutics plc...